Skip to content
2000
Volume 24, Issue 3
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Depression is a chronic and recurrent psychiatric condition believed to result from an interaction between genetic susceptibility and environmental stimuli. Although current therapies prescribed for depression can be effective, it will take several weeks to demonstrate their full effectiveness and is often accompanied by side effects and withdrawal symptoms. In this regard, the discovery of new antidepressant drugs with unique, higher curative effects and fewer adverse reactions is the pursuit of pharmaceuticals. Trace amine-associated receptor 1 (TAAR1), a G-protein coupled receptor (GPCR) that is broadly expressed in the mammalian brain, especially within cortical, limbic, and midbrain monoaminergic regions and activated by “trace amines” (TAs). It is allegedly involved in modulating dopaminergic, serotonergic, and glutamatergic transmission, which makes TAAR1 a new drug target for the treatment of dysfunction of monoamine-related disorders. Moreover, TAAR1 agonists have attracted interest as potential treatments for depression due to their role in regulating monoamine neurotransmission. In fact, Ulotaront (a TAAR1 agonist) is reported to be currently undergoing phase 2/3 clinical trials in order to test its safety and efficacy in the treatment of major depressive disorder (MDD). However, the final results of this Phase 2/3 clinical study have not been announced yet, and the efficacy and safety of Ulotaront in the treatment of depression still need further observation and research. Thus, this article aims to review evidence of the potential role of TAAR1 in the pathophysiology and treatment of depression. Moreover, we briefly summarize the recent findings in the elucidation of behavioral and physiological properties of TAAR1 agonists both in clinical trials and preclinical animal studies. Collectively, these studies will provide a solid foundation for TAAR1 as a novel therapeutic target for depression.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X370669250526115723
2025-06-23
2026-03-04

  • From This Site

    /content/journals/cn/10.2174/011570159X370669250526115723
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FerrariA.J. CharlsonF.J. NormanR.E. PattenS.B. FreedmanG. MurrayC.J.L. VosT. WhitefordH.A. Burden of depressive disorders by country, sex, age, and year: Findings from the global burden of disease study 2010.PLoS Med.20131011e100154710.1371/journal.pmed.1001547 24223526
     [Google Scholar]
  2. RuderferD.M. WalshC.G. AguirreM.W. TanigawaY. RibeiroJ.D. FranklinJ.C. RivasM.A. Significant shared heritability underlies suicide attempt and clinically predicted probability of attempting suicide.Mol. Psychiatry202025102422243010.1038/s41380‑018‑0326‑8 30610202
     [Google Scholar]
  3. TsunoN. BessetA. RitchieK. Sleep and depression.J. Clin. Psychiatry200566101254126910.4088/JCP.v66n1008 16259539
     [Google Scholar]
  4. ElliottA.F. HellM.D. Sheldrick-MichelA. NielsenB. Cognitive impairment after depression leads to disability.Ugeskr. Laeger201617845V05160316 27855769
     [Google Scholar]
  5. MillwardL.J. LutteA. PurvisR.G. Depression and the perpetuation of an incapacitated identity as an inhibitor of return to work.J. Psychiatr. Ment. Health Nurs.200512556557310.1111/j.1365‑2850.2005.00875.x 16164507
     [Google Scholar]
  6. SamaanZ. MacQueenG. Depression, migraine, and cardiovascular disease: Sadness really can break your heart.J. Psychosom. Res.200865210310610.1016/j.jpsychores.2008.06.008 18655853
     [Google Scholar]
  7. ConnorT.J. LeonardB.E. Depression, stress and immunological activation: The role of cytokines in depressive disorders.Life Sci.199862758360610.1016/S0024‑3205(97)00990‑9 9472719
     [Google Scholar]
  8. KlengelT. BinderE.B. Epigenetics of stress-related psychiatric disorders and gene × environment interactions.Neuron20158661343135710.1016/j.neuron.2015.05.036 26087162
     [Google Scholar]
  9. ColeJ. CostafredaS.G. McGuffinP. FuC.H.Y. Hippocampal atrophy in first episode depression: A meta-analysis of magnetic resonance imaging studies.J. Affect. Disord.20111341-348348710.1016/j.jad.2011.05.057 21745692
     [Google Scholar]
  10. VidebechP. RavnkildeB. Hippocampal volume and depression: A meta-analysis of MRI studies.Am. J. Psychiatry2004161111957196610.1176/appi.ajp.161.11.1957 15514393
     [Google Scholar]
  11. StockmeierC.A. MahajanG.J. KonickL.C. OverholserJ.C. JurjusG.J. MeltzerH.Y. UylingsH.B.M. FriedmanL. RajkowskaG. Cellular changes in the postmortem hippocampus in major depression.Biol. Psychiatry200456964065010.1016/j.biopsych.2004.08.022 15522247
     [Google Scholar]
  12. ZhuR. FangY. LiH. LiuY. WeiJ. ZhangS. WangL. FanR. WangL. LiS. ChenT. Psychobiotic Lactobacillus plantarum JYLP-326 relieves anxiety, depression, and insomnia symptoms in test anxious college via modulating the gut microbiota and its metabolism.Front. Immunol.202314115813710.3389/fimmu.2023.1158137 37033942
     [Google Scholar]
  13. DeanJ. KeshavanM. The neurobiology of depression: An integrated view.Asian J. Psychiatr.20172710111110.1016/j.ajp.2017.01.025 28558878
     [Google Scholar]
  14. CuijpersP. van StratenA. AnderssonG. van OppenP. Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies.J. Consult. Clin. Psychol.200876690992210.1037/a0013075 19045960
     [Google Scholar]
  15. FavaG.A. RuiniC. RafanelliC. FinosL. ContiS. GrandiS. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression.Am. J. Psychiatry2004161101872187610.1176/ajp.161.10.1872 15465985
     [Google Scholar]
  16. KennedyS.H. LamR.W. McIntyreR.S. TourjmanS.V. BhatV. BlierP. HasnainM. JollantF. LevittA.J. MacQueenG.M. McInerneyS.J. McIntoshD. MilevR.V. MüllerD.J. ParikhS.V. PearsonN.L. RavindranA.V. UherR. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder.Can. J. Psychiatry201661954056010.1177/0706743716659417 27486148
     [Google Scholar]
  17. TouloumisC. The burden and the challenge of treatment-resistant depression.Psychiatriki2021321114(Suppl. 1)10.22365/jpsych.2021.046 34990376
     [Google Scholar]
  18. BoultonA.A. JuorioA.V. Brain Trace Amines, Chemical and Cellular Architecture.Springer198218922210.1007/978‑1‑4757‑0614‑7_8
     [Google Scholar]
  19. BorowskyB. AdhamN. JonesK.A. RaddatzR. ArtymyshynR. OgozalekK.L. DurkinM.M. LakhlaniP.P. BoniniJ.A. PathiranaS. BoyleN. PuX. KouranovaE. LichtblauH. OchoaF.Y. BranchekT.A. GeraldC. Trace amines: Identification of a family of mammalian G protein-coupled receptors.Proc. Natl. Acad. Sci. USA200198168966897110.1073/pnas.151105198 11459929
     [Google Scholar]
  20. PhilipsS. Analysis of Trace Amines: Endogenous Levels and the Effects of Various Drugs on Tissue Concentrations in the Rat, Neurobiology of the Trace Amines: Analytical, Physiological, Pharmacological, Behavioral, and Clinical Aspects.Springer1984127143
     [Google Scholar]
  21. BurchettS.A. HicksT.P. The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain.Prog. Neurobiol.2006795-622324610.1016/j.pneurobio.2006.07.003 16962229
     [Google Scholar]
  22. BoultonA.A. Trace amines and mental disorders.Can. J. Neurol. Sci.19807326126310.1017/S0317167100023313 7004611
     [Google Scholar]
  23. DavisB.A. BoultonA.A. The trace amines and their acidic metabolites in depression — An overview.Prog. Neuropsychopharmacol. Biol. Psychiatry1994181174510.1016/0278‑5846(94)90022‑1 8115671
     [Google Scholar]
  24. SabelliH. FinkP. FawcettJ. TomC. Sustained antidepressant effect of PEA replacement.J. Neuropsychiatry Clin. Neurosci.19968216817110.1176/jnp.8.2.168 9081552
     [Google Scholar]
  25. LindemannL. HoenerM.C. A renaissance in trace amines inspired by a novel GPCR family.Trends Pharmacol. Sci.200526527428110.1016/j.tips.2005.03.007 15860375
     [Google Scholar]
  26. GrandyD.K. Trace amine-associated receptor 1—Family archetype or iconoclast?Pharmacol. Ther.2007116335539010.1016/j.pharmthera.2007.06.007 17888514
     [Google Scholar]
  27. GrabiecM. TurlejskiK. DjavadianR.L. The partial 5-HT1A receptor agonist buspirone enhances neurogenesis in the opossum (Monodelphis domestica).Eur. Neuropsychopharmacol.200919643143910.1016/j.euroneuro.2009.01.013 19249192
     [Google Scholar]
  28. LindemannL. EbelingM. KratochwilN.A. BunzowJ.R. GrandyD.K. HoenerM.C. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors.Genomics200585337238510.1016/j.ygeno.2004.11.010 15718104
     [Google Scholar]
  29. BerryM.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators.J. Neurochem.200490225727110.1111/j.1471‑4159.2004.02501.x 15228583
     [Google Scholar]
  30. LindemannL. MeyerC.A. JeanneauK. BradaiaA. OzmenL. BluethmannH. BettlerB. WettsteinJ.G. BorroniE. MoreauJ.L. HoenerM.C. Trace amine-associated receptor 1 modulates dopaminergic activity.J. Pharmacol. Exp. Ther.2008324394895610.1124/jpet.107.132647 18083911
     [Google Scholar]
  31. EspinozaS. GhisiV. EmanueleM. LeoD. SukhanovI. SotnikovaT.D. ChieregattiE. GainetdinovR.R. Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1.Neuropharmacology20159330831310.1016/j.neuropharm.2015.02.010 25721394
     [Google Scholar]
  32. EspinozaS. LignaniG. CaffinoL. MaggiS. SukhanovI. LeoD. MusL. EmanueleM. RonzittiG. HarmeierA. MedrihanL. SotnikovaT.D. ChieregattiE. HoenerM.C. BenfenatiF. TucciV. FumagalliF. GainetdinovR.R. TAAR1 modulates cortical glutamate NMDA receptor function.Neuropsychopharmacology20154092217222710.1038/npp.2015.65 25749299
     [Google Scholar]
  33. PittsM.S. McShaneJ.N. HoenerM.C. ChristianS.L. BerryM.D. TAAR1 levels and sub-cellular distribution are cell line but not breast cancer subtype specific.Histochem. Cell Biol.2019152215516610.1007/s00418‑019‑01791‑7 31111198
     [Google Scholar]
  34. LiuJ. WuR. LiJ.X. TAAR1 as an emerging target for the treatment of psychiatric disorders.Pharmacol. Ther.202425310858010.1016/j.pharmthera.2023.108580 38142862
     [Google Scholar]
  35. GrandyD.K. MillerG.M. LiJ.X. “TAARgeting Addiction”—the alamo bears witness to another revolution.Drug Alcohol Depend.201615991610.1016/j.drugalcdep.2015.11.014 26644139
     [Google Scholar]
  36. ZhangY. ZhangX.Q. NiuW.P. SunM. ZhangY. LiJ.T. SiT.M. SuY.A. TAAR1 in dentate gyrus is involved in chronic stress-induced impairments in hippocampal plasticity and cognitive function.Prog. Neuropsychopharmacol. Biol. Psychiatry202413211099510.1016/j.pnpbp.2024.110995 38514038
     [Google Scholar]
  37. RenX. XiongJ. LiangL. ChenY. ZhangG. The potential antidepressant action of duloxetine co-administered with the TAAR1 receptor agonist SEP-363856 in mice.Molecules2022279275510.3390/molecules27092755 35566106
     [Google Scholar]
  38. LeG.H. GillissieE.S. RheeT.G. CaoB. AlnefeesiY. GuoZ. Di VincenzoJ.D. JawadM.Y. MarchA.M. RamachandraR. LuiL.M.W. McIntyreR.S. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: A systematic review of preclinical and clinical trials.Expert Opin. Investig. Drugs202332540141510.1080/13543784.2023.2206559 37096491
     [Google Scholar]
  39. UnderhillS.M. HullihenP.D. ChenJ. Fenollar-FerrerC. RizzoM.A. IngramS.L. AmaraS.G. Amphetamines signal through intracellular TAAR1 receptors coupled to Gα13 and GαS in discrete subcellular domains.Mol. Psychiatry20212641208122310.1038/s41380‑019‑0469‑2 31399635
     [Google Scholar]
  40. ZhengY. YasudaM. YamaoM. GokanT. SejimaY. NishikawaT. KatayamaS. Fermented soybean foods (natto) ameliorate age-related cognitive decline by hippocampal TAAR1-mediated activation of the CaMKII/CREB/BDNF signaling pathway in senescence-accelerated mouse prone 8 (SAMP8).Food Funct.20231422100971010610.1039/D3FO03987K 37870125
     [Google Scholar]
  41. PanasM.W. XieZ. PanasH.N. HoenerM.C. VallenderE.J. MillerG.M. Trace amine associated receptor 1 signaling in activated lymphocytes.J. Neuroimmune Pharmacol.20127486687610.1007/s11481‑011‑9321‑4 22038157
     [Google Scholar]
  42. BradaiaA. TrubeG. StalderH. NorcrossR.D. OzmenL. WettsteinJ.G. PinardA. BuchyD. GassmannM. HoenerM.C. BettlerB. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.Proc. Natl. Acad. Sci. USA200910647200812008610.1073/pnas.0906522106 19892733
     [Google Scholar]
  43. YangW. MunhallA.C. JohnsonS.W. Dopamine evokes a trace amine receptor-dependent inward current that is regulated by AMP kinase in substantia nigra dopamine neurons.Neuroscience2020427779110.1016/j.neuroscience.2019.11.044 31883822
     [Google Scholar]
  44. BunzowJ.R. SondersM.S. ArttamangkulS. HarrisonL.M. ZhangG. QuigleyD.I. DarlandT. SuchlandK.L. PasumamulaS. KennedyJ.L. OlsonS.B. MagenisR.E. AmaraS.G. GrandyD.K. Amphetamine, 3,4-methylenedioxymethampheta-mine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.Mol. Pharmacol.20016061181118810.1124/mol.60.6.1181 11723224
     [Google Scholar]
  45. SukhanovI. CaffinoL. EfimovaE.V. EspinozaS. SotnikovaT.D. CervoL. FumagalliF. GainetdinovR.R. Increased context-dependent conditioning to amphetamine in mice lacking TAAR1.Pharmacol. Res.201610320621410.1016/j.phrs.2015.11.002 26640076
     [Google Scholar]
  46. PeiY. Asif-MalikA. CanalesJ.J. Trace amines and the trace amine-associated receptor 1: Pharmacology, neurochemistry, and clinical implications.Front. Neurosci.20161014810.3389/fnins.2016.00148 27092049
     [Google Scholar]
  47. ReeseE.A. BunzowJ.R. ArttamangkulS. SondersM.S. GrandyD.K. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.J. Pharmacol. Exp. Ther.2007321117818610.1124/jpet.106.115402 17218486
     [Google Scholar]
  48. ShiX. WalterN.A.R. HarknessJ.H. NeveK.A. WilliamsR.W. LuL. BelknapJ.K. EshlemanA.J. PhillipsT.J. JanowskyA. Genetic polymorphisms affect mouse and human trace amine-associated receptor 1 function.PLoS One2016113e015258110.1371/journal.pone.0152581 27031617
     [Google Scholar]
  49. HalffE.F. RutiglianoG. Garcia-HidalgoA. HowesO.D. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.Trends Neurosci.2023461607410.1016/j.tins.2022.10.010 36369028
     [Google Scholar]
  50. EspinozaS. SalahpourA. MasriB. SotnikovaT.D. MessaM. BarakL.S. CaronM.G. GainetdinovR.R. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor.Mol. Pharmacol.201180341642510.1124/mol.111.073304 21670104
     [Google Scholar]
  51. LeoD. MusL. EspinozaS. HoenerM.C. SotnikovaT.D. GainetdinovR.R. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors.Neuropharmacology20148128329110.1016/j.neuropharm.2014.02.007 24565640
     [Google Scholar]
  52. HarmeierA. ObermuellerS. MeyerC.A. RevelF.G. BuchyD. ChabozS. DernickG. WettsteinJ.G. IglesiasA. RolinkA. BettlerB. HoenerM.C. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers.Eur. Neuropsychopharmacol.201525112049206110.1016/j.euroneuro.2015.08.011 26372541
     [Google Scholar]
  53. Asif-MalikA. HoenerM.C. CanalesJ.J. Interaction between the trace amine-associated receptor 1 and the dopamine D2 receptor controls cocaine’s neurochemical actions.Sci. Rep.2017711390110.1038/s41598‑017‑14472‑z 29066851
     [Google Scholar]
  54. JopeR.S. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.Front. Mol. Neurosci.201141610.3389/fnmol.2011.00016 21886606
     [Google Scholar]
  55. GallagherM. ChibaA.A. The amygdala and emotion.Curr. Opin. Neurobiol.19966222122710.1016/S0959‑4388(96)80076‑6 8725964
     [Google Scholar]
  56. BoultonA.A. MilwardL. Separation, detection and quantitative, analysis of urinary β-phenylethylamine.J. Chromatogr. A197157228729610.1016/0021‑9673(71)80042‑0 5575724
     [Google Scholar]
  57. AlnefeesiY. TamuraJ.K. LuiL.M.W. JawadM.Y. CebanF. LingS. NasriF. RosenblatJ.D. McIntyreR.S. Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review.Neurosci. Biobehav. Rev.202113119221010.1016/j.neubiorev.2021.09.020 34537265
     [Google Scholar]
  58. PorsoltR.D. Le PichonM. JalfreM. Depression: A new animal model sensitive to antidepressant treatments.Nature1977266560473073210.1038/266730a0 559941
     [Google Scholar]
  59. KokkinouM. IrvineE.E. BonsallD.R. NatesanS. WellsL.A. SmithM. GlegolaJ. PaulE.J. TossellK. VeroneseM. KhadayateS. DedicN. HopkinsS.C. UnglessM.A. WithersD.J. HowesO.D. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: A translational imaging study with ketamine.Mol. Psychiatry20212662562257610.1038/s41380‑020‑0740‑6 32382134
     [Google Scholar]
  60. HopkinsS.C. DedicN. KoblanK.S. Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans.Transl. Psychiatry202111122810.1038/s41398‑021‑01331‑9 33879769
     [Google Scholar]
  61. RevelF.G. MoreauJ.L. GainetdinovR.R. BradaiaA. SotnikovaT.D. MoryR. DurkinS. ZbindenK.G. NorcrossR. MeyerC.A. MetzlerV. ChabozS. OzmenL. TrubeG. PouzetB. BettlerB. CaronM.G. WettsteinJ.G. HoenerM.C. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.Proc. Natl. Acad. Sci. USA2011108208485849010.1073/pnas.1103029108 21525407
     [Google Scholar]
  62. DedicN. JonesP.G. HopkinsS.C. LewR. ShaoL. CampbellJ.E. SpearK.L. LargeT.H. CampbellU.C. HananiaT. LeahyE. KoblanK.S. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action.J. Pharmacol. Exp. Ther.2019371111410.1124/jpet.119.260281 31371483
     [Google Scholar]
  63. GottesmannC. GottesmanI. The neurobiological characteristics of rapid eye movement (REM) sleep are candidate endophenotypes of depression, schizophrenia, mental retardation and dementia.Prog. Neurobiol.200781423725010.1016/j.pneurobio.2007.01.004 17350744
     [Google Scholar]
  64. FeemsterJ.C. WesterlandS.M. GossardT.R. SteeleT.A. TimmP.C. JagielskiJ.T. StrainisE. McCarterS.J. HopkinsS.C. KoblanK.S. St LouisE.K. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.Sleep Med.202310157858610.1016/j.sleep.2022.11.022 36584503
     [Google Scholar]
  65. SateiaM.J. International classification of sleep disorders-third edition: Highlights and modifications.Chest201414651387139410.1378/chest.14‑0970 25367475
     [Google Scholar]
  66. MombelliS. RicordeauF. GillardL. LeccaR. VidalT. PereiraB. BeudinP. VitelloN. BastujiH. Peter-DerexL. FantiniM.L. Psychobehavioural profile in narcolepsy type 1 with and without REM sleep behaviour disorder.J. Sleep Res.2024332e1392510.1111/jsr.13925 37222001
     [Google Scholar]
  67. EspinozaS. LeoD. SotnikovaT.D. ShahidM. KääriäinenT.M. GainetdinovR.R. Biochemical and functional characterization of the trace amine-associated receptor 1 (TAAR1) agonist RO5263397.Front. Pharmacol.2018964510.3389/fphar.2018.00645 29977204
     [Google Scholar]
  68. SunM. ZhangY. ZhangX.Q. ZhangY. WangX.D. LiJ.T. SiT.M. SuY.A. Dopamine D1 receptor in medial prefrontal cortex mediates the effects of TAAR1 activation on chronic stress-induced cognitive and social deficits.Neuropsychopharmacology20244981341135110.1038/s41386‑024‑01866‑7 38658737
     [Google Scholar]
  69. ZhangY. LiJ.T. WangH. NiuW.P. ZhangC.C. ZhangY. WangX.D. SiT.M. SuY.A. Role of trace amine associated receptor 1 in the medial prefrontal cortex in chronic social stress-induced cognitive deficits in mice.Pharmacol. Res.202116710557110.1016/j.phrs.2021.105571 33753244
     [Google Scholar]
  70. RocaM. VivesM. López-NavarroE. García-CampayoJ. GiliM. Cognitive impairments and depression: A critical review.Actas Esp. Psiquiatr.2015435187193 26320897
     [Google Scholar]
  71. GrinchiiD. HoenerM.C. KhouryT. DekhtiarenkoR. Nejati BervanlouR. JezovaD. DremencovE. Effects of acute and chronic administration of trace amine-associated receptor 1 (TAAR1) ligands on in vivo excitability of central monoamine-secreting neurons in rats.Mol. Psychiatry202227124861486810.1038/s41380‑022‑01739‑9 36045279
     [Google Scholar]
  72. RevelF.G. MoreauJ-L. PouzetB. MoryR. BradaiaA. BuchyD. MetzlerV. ChabozS. Groebke ZbindenK. GalleyG. NorcrossR.D. TuerckD. BrunsA. MorairtyS.R. KilduffT.S. WallaceT.L. RisterucciC. WettsteinJ.G. HoenerM.C. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Mol. Psychiatry201318554355610.1038/mp.2012.57 22641180
     [Google Scholar]
  73. SchwartzM.D. BlackS.W. FisherS.P. PalmerstonJ.B. MorairtyS.R. HoenerM.C. KilduffT.S. Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition.Neuropsychopharmacology20174261305131410.1038/npp.2016.216 27658486
     [Google Scholar]
  74. BlackS.W. SchwartzM.D. ChenT.M. HoenerM.C. KilduffT.S. Trace amine-associated receptor 1 agonists as narcolepsy therapeutics.Biol. Psychiatry201782962363310.1016/j.biopsych.2016.10.012 27919403
     [Google Scholar]
  75. RevelF.G. MoreauJ.L. GainetdinovR.R. FerragudA. Velázquez-SánchezC. SotnikovaT.D. MorairtyS.R. HarmeierA. Groebke ZbindenK. NorcrossR.D. BradaiaA. KilduffT.S. BiemansB. PouzetB. CaronM.G. CanalesJ.J. WallaceT.L. WettsteinJ.G. HoenerM.C. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.Biol. Psychiatry2012721193494210.1016/j.biopsych.2012.05.014 22705041
     [Google Scholar]
  76. LiS.X. YanS.Y. BaoY.P. LianZ. QuZ. WuY.P. LiuZ.M. Depression and alterations in hypothalamic-pituitary-adrenal and hypothalamic-pituitary-thyroid axis function in male abstinent methamphetamine abusers.Hum. Psychopharmacol.201328547748310.1002/hup.2335 23913817
     [Google Scholar]
  77. CotterR. PeiY. MusL. HarmeierA. GainetdinovR.R. HoenerM.C. CanalesJ.J. The trace amine-associated receptor 1 modulates methamphetamine’s neurochemical and behavioral effects.Front. Neurosci.201593910.3389/fnins.2015.00039 25762894
     [Google Scholar]
  78. LiuJ. JohnsonB. WuR. SeamanR. VuJ. ZhuQ. ZhangY. LiJ.X. TA1 agonists attenuate extended‐access cocaine self‐administration and yohimbine‐induced reinstatement of cocaine‐seeking.Br. J. Pharmacol.2020177153403341410.1111/bph.15061 32246467
     [Google Scholar]
  79. Barbosa MéndezS. Salazar-JuárezA. Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal.J. Psychopharmacol.201933558960510.1177/0269881119840521 31012359
     [Google Scholar]
  80. BossertJ.M. MarchantN.J. CaluD.J. ShahamY. The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research.Psychopharmacology2013229345347610.1007/s00213‑013‑3120‑y 23685858
     [Google Scholar]
  81. NairS.G. NavarreB.M. CifaniC. PickensC.L. BossertJ.M. ShahamY. Role of dorsal medial prefrontal cortex dopamine D1-family receptors in relapse to high-fat food seeking induced by the anxiogenic drug yohimbine.Neuropsychopharmacology201136249751010.1038/npp.2010.181 20962767
     [Google Scholar]
  82. LiuJ.F. SiemianJ.N. SeamanR. ZhangY. LiJ.X. Role of TAAR1 within the subregions of the mesocorticolimbic dopaminergic system in cocaine-seeking behavior.J. Neurosci.201737488289210.1523/JNEUROSCI.2006‑16.2016 28123023
     [Google Scholar]
  83. AmbroggiF. GhazizadehA. NicolaS.M. FieldsH.L. Roles of nucleus accumbens core and shell in incentive-cue responding and behavioral inhibition.J. Neurosci.201131186820683010.1523/JNEUROSCI.6491‑10.2011 21543612
     [Google Scholar]
  84. FuchsR.A. EvansK.A. ParkerM.C. SeeR.E. Differential involvement of the core and shell subregions of the nucleus accumbens in conditioned cue-induced reinstatement of cocaine seeking in rats.Psychopharmacology20041763-445946510.1007/s00213‑004‑1895‑6 15138757
     [Google Scholar]
  85. HartM.E. SuchlandK.L. MiyakawaM. BunzowJ.R. GrandyD.K. ScanlanT.S. Trace amine-associated receptor agonists: Synthesis and evaluation of thyronamines and related analogues.J. Med. Chem.20064931101111210.1021/jm0505718 16451074
     [Google Scholar]
  86. MantasI. MillanM.J. Di CaraB. GroeninkL. VeigaS. CistarelliL. BroccoM. BertrandM. SvenningssonP. ZhangX. Trace amine-associated receptor 1 contributes to diverse functional actions of O-phenyl-iodotyramine in mice but not to the effects of monoamine-based antidepressants.Int. J. Mol. Sci.20212216890710.3390/ijms22168907 34445611
     [Google Scholar]
  87. KongQ. ZhangH. WangM. ZhangJ. ZhangY. The TAAR1 inhibitor EPPTB suppresses neuronal excitability and seizure activity in mice.Brain Res. Bull.202117114214910.1016/j.brainresbull.2021.03.018 33811954
     [Google Scholar]
  88. LiuJ. MengF. WangW. CuiM. WuM. JiangS. DaiJ. LianH. LiQ. XuZ. WangY. ZhangJ. LiC. PPM1F in hippocampal dentate gyrus regulates the depression-related behaviors by modulating neuronal excitability.Exp. Neurol.202134011365710.1016/j.expneurol.2021.113657 33639208
     [Google Scholar]
  89. StalderH. HoenerM.C. NorcrossR.D. Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): Discovery of EPPTB (RO5212773).Bioorg. Med. Chem. Lett.20112141227123110.1016/j.bmcl.2010.12.075 21237643
     [Google Scholar]
  90. LanducciE. GencarelliM. MazzantiniC. LaurinoA. Pellegrini-GiampietroD.E. RaimondiL.N. -(3-Ethoxy-phenyl)-4-pyrrolidin-1-yl-3-trifluoromethyl-benzamide (EPPTB) prevents 3-iodothyronamine (T1AM)-induced neuroprotection against kainic acid toxicity.Neurochem. Int.201912910446010.1016/j.neuint.2019.05.004 31075293
     [Google Scholar]
  91. GencarelliM. LodoviciM. BellusciL. RaimondiL. LaurinoA. Redox properties of 3-iodothyronamine (T1AM) and 3-iodothyroacetic acid (TA1).Int. J. Mol. Sci.2022235271810.3390/ijms23052718 35269859
     [Google Scholar]
  92. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.Lancet2015386999574380010.1016/S0140‑6736(15)60692‑4 26063472
     [Google Scholar]
  93. KuvarzinS.R. SukhanovI. OnokhinK. ZakharovK. GainetdinovR.R. Unlocking the therapeutic potential of ulotaront as a trace amine-associated receptor 1 agonist for neuropsychiatric disorders.Biomedicines2023117197710.3390/biomedicines11071977 37509616
     [Google Scholar]
  94. HøjlundM. CorrellC.U. Ulotaront: A TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.Expert Opin. Investig. Drugs202231121279129010.1080/13543784.2022.2158811 36533396
     [Google Scholar]
  95. QiW. GuanW. GPR56: A potential therapeutic target for neurological and psychiatric disorders.Biochem. Pharmacol.202422611639510.1016/j.bcp.2024.116395 38942087
     [Google Scholar]
  96. XueZ. SiemianJ.N. JohnsonB.N. ZhangY. LiJ.X. Methamphetamine-induced impulsivity during chronic methamphetamine treatment in rats: Effects of the TAAR 1 agonist RO5263397.Neuropharmacology2018129364610.1016/j.neuropharm.2017.11.012 29128305
     [Google Scholar]
  97. FerragudA. HowellA.D. MooreC.F. TaT.L. HoenerM.C. SabinoV. CottoneP. The trace amine-associated receptor 1 agonist RO5256390 blocks compulsive, binge-like eating in rats.Neuropsychopharmacology20174271458147010.1038/npp.2016.233 27711047
     [Google Scholar]
/content/journals/cn/10.2174/011570159X370669250526115723
Loading
The Role of Trace Amine-Associated Receptor 1 (TAAR1) in the Pathophysiology and Treatment of Depression
Curr. Neuropharmacol. 24, 295 (2026); https://doi.org/10.2174/011570159X370669250526115723
/content/journals/cn/10.2174/011570159X370669250526115723
/content/journals/cn/10.2174/011570159X370669250526115723
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): antidepressant; Depression; neuropsychiatric disorders; signalling pathway; TAAR1; ulotaront

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test